Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine | Zendy

Barney S. Graham | Zendy; Richard A. Koup | Zendy; Mario Roederer | Zendy; Robert T. Bailer | Zendy; Mary E. Enama | Zendy; Zoe Moodie | Zendy; Julie E. Martin | Zendy; Margaret McCluskey | Zendy; Bimal K. Chakrabarti | Zendy; Laurie Lamoreaux | Zendy; Charla Andrews | Zendy; Phillip L. Gomez | Zendy; John R. Mascola | Zendy; Gary J. Nabel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 DNA Candidate Vaccine

Author(s) -

Barney S. Graham,

Richard A. Koup,

Mario Roederer,

Robert T. Bailer,

Mary E. Enama,

Zoe Moodie,

Julie E. Martin,

Margaret McCluskey,

Bimal K. Chakrabarti,

Laurie Lamoreaux,

Charla Andrews,

Phillip L. Gomez,

John R. Mascola,

Gary J. Nabel

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/509259

Subject(s) - immunogenicity , dna vaccination , virology , hiv vaccine , vaccination , elispot , immunology , biology , antibody , antigen , medicine , cd8 , vaccine trial , immunization

Gene-based vaccine delivery is an important strategy in the development of a preventive vaccine for acquired immunodeficiency syndrome (AIDS). Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research